Positive News SentimentPositive NewsNASDAQ:BMEA Biomea Fusion (BMEA) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free BMEA Stock Alerts $10.83 -0.02 (-0.18%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$10.81▼$11.2850-Day Range$10.83▼$18.8552-Week Range$8.13▼$43.69Volume603,210 shsAverage Volume998,347 shsMarket Capitalization$388.68 millionP/E RatioN/ADividend YieldN/APrice Target$53.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Biomea Fusion alerts: Email Address Biomea Fusion MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside390.5% Upside$53.13 Price TargetShort InterestBearish47.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.25) to ($3.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.83 out of 5 starsMedical Sector596th out of 909 stocksPharmaceutical Preparations Industry266th out of 421 stocks 3.4 Analyst's Opinion Consensus RatingBiomea Fusion has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageBiomea Fusion has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted47.76% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.Change versus previous monthShort interest in Biomea Fusion has recently increased by 18.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiomea Fusion does not currently pay a dividend.Dividend GrowthBiomea Fusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BMEA. Previous Next 2.7 News and Social Media Coverage News SentimentBiomea Fusion has a news sentiment score of 1.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Biomea Fusion this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for BMEA on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is a decrease of -21% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biomea Fusion insiders have not sold or bought any company stock.Percentage Held by Insiders26.27% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biomea Fusion are expected to grow in the coming year, from ($4.25) to ($3.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomea Fusion is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomea Fusion is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomea Fusion has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Biomea Fusion Stock (NASDAQ:BMEA)Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Read More BMEA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMEA Stock News HeadlinesApril 16, 2024 | americanbankingnews.comBiomea Fusion, Inc. (NASDAQ:BMEA) Sees Significant Growth in Short InterestApril 4, 2024 | msn.com3 Best Stocks to Buy Now, 4/4/2024, According to Top AnalystsApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Biomea Fusion on Promising BMF-219 Clinical Results and Strong Financial PositionApril 1, 2024 | globenewswire.comBiomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | investorplace.comBMEA Stock Earnings: Biomea Fusion Misses EPS for Q4 2023April 1, 2024 | benzinga.comRecap: Biomea Fusion Q4 EarningsApril 1, 2024 | globenewswire.comBiomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219April 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 1, 2024 | globenewswire.comBiomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsMarch 17, 2024 | finance.yahoo.comBMEA Apr 2024 5.000 putMarch 17, 2024 | finance.yahoo.comBMEA Apr 2024 5.000 callMarch 7, 2024 | investorplace.com7 Short-Squeeze Stocks That Could Send the Bears Into Panic-ModeMarch 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biomea Fusion (BMEA) and Jasper Therapeutics (JSPR)March 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Biomea Fusion on Promising BMF-219 Clinical Trial Outcomes and Strong Safety ProfileMarch 6, 2024 | finance.yahoo.comBiomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic FunctionMarch 6, 2024 | globenewswire.comBiomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic FunctionMarch 1, 2024 | markets.businessinsider.comBiomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | globenewswire.comBiomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)February 27, 2024 | seekingalpha.comWhy Biomea Fusion Is A 'Hold': A Bet On Diabetes And Oncology ResearchFebruary 19, 2024 | markets.businessinsider.comFeeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch ForFebruary 18, 2024 | investorplace.com3 Speculative Stocks That Could Make Your February UnforgettableFebruary 7, 2024 | markets.businessinsider.comDissecting My Biomea Fusion (NASDAQ:BMEA) Options Trade: Tips, Tricks, and Lessons LearnedJanuary 10, 2024 | theglobeandmail.comWall Street Expects 190% Upside for This Biotech StockJanuary 9, 2024 | finanznachrichten.deBiomea Fusion, Inc.: Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219January 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Biomea Fusion Amid Promising Clinical TrialsJanuary 9, 2024 | finance.yahoo.comBiomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare ConferenceSee More Headlines Receive BMEA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today4/22/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BMEA CUSIPN/A CIK1840439 Webwww.biomeafusion.com Phone650-980-9099FaxN/AEmployees103Year FoundedN/APrice Target and Rating Average Stock Price Target$53.13 High Stock Price Target$90.00 Low Stock Price Target$14.00 Potential Upside/Downside+390.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,250,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-69.35% Return on Assets-59.65% Debt Debt-to-Equity RatioN/A Current Ratio7.84 Quick Ratio7.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.74 per share Price / Book2.28Miscellaneous Outstanding Shares35,889,000Free Float26,461,000Market Cap$388.68 million OptionableOptionable Beta-0.53 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Thomas Andrew Butler (Age 43)Co-Founder, Chairman & CEO Comp: $921.14kMr. Ramses M. Erdtmann (Age 61)Co-Founder, President, COO & Director Comp: $659.53kMr. Franco Valle (Age 43)CFO & Principal Accounting Officer Comp: $651.77kMr. Heow Tan (Age 65)Chief Technology & Quality Officer Ms. Naomi CretcherChief People OfficerDr. Thorsten Kirschberg Ph.D. (Age 54)Executive Vice President of Chemistry Dr. Stephan Morris M.D.Chief Development OfficerMr. Ravi UpasaniExecutive Vice President of Intellectual PropertyDr. Juan Pablo Frias M.D.Chief Medical OfficerCaroline Perez- DupontSenior Vice President of ContractsMore ExecutivesKey CompetitorsEntrada TherapeuticsNASDAQ:TRDAHarrow HealthNASDAQ:HROWLexicon PharmaceuticalsNASDAQ:LXRXHeron TherapeuticsNASDAQ:HRTXPepGenNASDAQ:PEPGView All CompetitorsInsiders & InstitutionsGriffin Asset Management Inc.Bought 10,700 shares on 4/17/2024Ownership: 0.106%PNC Financial Services Group Inc.Bought 8,000 shares on 3/22/2024Ownership: 0.022%Centaurus Financial Inc.Bought 7,014 shares on 2/26/2024Ownership: 0.020%Bellevue Group AGBought 25,000 shares on 2/14/2024Ownership: 0.070%Rafferty Asset Management LLCSold 132,169 shares on 2/13/2024Ownership: 0.285%View All Insider TransactionsView All Institutional Transactions BMEA Stock Analysis - Frequently Asked Questions Should I buy or sell Biomea Fusion stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BMEA shares. View BMEA analyst ratings or view top-rated stocks. What is Biomea Fusion's stock price target for 2024? 8 Wall Street research analysts have issued 1-year price objectives for Biomea Fusion's shares. Their BMEA share price targets range from $14.00 to $90.00. On average, they anticipate the company's stock price to reach $53.13 in the next year. This suggests a possible upside of 390.5% from the stock's current price. View analysts price targets for BMEA or view top-rated stocks among Wall Street analysts. How have BMEA shares performed in 2024? Biomea Fusion's stock was trading at $14.52 on January 1st, 2024. Since then, BMEA shares have decreased by 25.4% and is now trading at $10.83. View the best growth stocks for 2024 here. Are investors shorting Biomea Fusion? Biomea Fusion saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 13,240,000 shares, an increase of 18.2% from the March 15th total of 11,200,000 shares. Based on an average daily volume of 1,020,000 shares, the short-interest ratio is presently 13.0 days. Currently, 47.8% of the company's shares are short sold. View Biomea Fusion's Short Interest. When is Biomea Fusion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our BMEA earnings forecast. How were Biomea Fusion's earnings last quarter? Biomea Fusion, Inc. (NASDAQ:BMEA) posted its earnings results on Tuesday, November, 2nd. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.04. When did Biomea Fusion IPO? Biomea Fusion (BMEA) raised $120 million in an initial public offering on Friday, April 16th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO. Who are Biomea Fusion's major shareholders? Biomea Fusion's stock is owned by a variety of retail and institutional investors. Top institutional investors include Griffin Asset Management Inc. (0.11%). Insiders that own company stock include A2a Pharmaceuticals, Inc, Bihua Chen, Franco Valle, Michael JM Hitchcock and Rainer M Erdtmann. View institutional ownership trends. How do I buy shares of Biomea Fusion? Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BMEA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
